<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759212</url>
  </required_header>
  <id_info>
    <org_study_id>AHEPA_CTL_02</org_study_id>
    <nct_id>NCT01759212</nct_id>
  </id_info>
  <brief_title>Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.</brief_title>
  <official_title>Safety and Efficacy of Intramyocardial Implantation of Allogeneic Mesenchymal Stem Cells in Patients With End-stage Heart Failure Undergoing Left Ventricular Assist Device Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate safety and efficacy of intramyocardial implantation of
      allogeneic mesenchymal stem cells in patients with end-stage ischemic cardiomyopathy
      undergoing left ventricular assist device implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End-stage ischemic cardiomyopathy (ICM) with non-graftable coronary arteries is a common and
      debilitating problem. The ultimate therapeutic goal in such cases is cardiac transplantation
      which is restricted by donor availability. Alternatively, left ventricular assist devices
      (LVAD) are increasingly used as bridge to transplantation or more recently as destination
      therapy in non-transplant candidates. Widely used second- and third-generation
      continuous-flow LVAD offer symptomatic relief and prolong life. However, LV unloading rarely
      improves native heart function in ischemic hearts. We aim to increase myocardial viability
      and improve native cardiac function in patients with end-stage ICM by injecting allogeneic
      bone marrow stem cells at the time of LVAD implantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in myocardial perfusion/viability</measure>
    <time_frame>one year</time_frame>
    <description>Improvement in myocardial perfusion/viability assessed with SPECT segmental analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause morbidity</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>one year</time_frame>
    <description>Change in left ventricular function after combined mechanical and cellular therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Stem cells implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic stem cells implantation</intervention_name>
    <arm_group_label>Stem cells implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 75 years

          -  End-stage heart failure due to ischemic cardiomyopathy that requires mechanical
             support according to current indications

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Not willing to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Anastasiadis, MD, DSc, FETCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Polychronis Antonitsis, MD, DSc</last_name>
    <phone>+30 2310 994871</phone>
    <email>antonits@auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polychronis Antonitsis, MD, DSc</last_name>
      <phone>+30 2310 994871</phone>
      <email>antonits@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Kyriakos Anastasiadis, MD, DSc, FETCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Polychronis Antonitsis, MD, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Anastasiadis K, Antonitsis P, Doumas A, Koliakos G, Argiriadou H, Vaitsopoulou C, Tossios P, Papakonstantinou C, Westaby S. Stem cells transplantation combined with long-term mechanical circulatory support enhances myocardial viability in end-stage ischemic cardiomyopathy. Int J Cardiol. 2012 Mar 22;155(3):e51-3. doi: 10.1016/j.ijcard.2011.07.062. Epub 2011 Aug 17.</citation>
    <PMID>21852003</PMID>
  </reference>
  <reference>
    <citation>Anastasiadis K, Antonitsis P, Argiriadou H, Koliakos G, Doumas A, Khayat A, Papakonstantinou C, Westaby S. Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J Transl Med. 2011 Jan 19;9:12. doi: 10.1186/1479-5876-9-12. Review.</citation>
    <PMID>21247486</PMID>
  </reference>
  <reference>
    <citation>Ibrahim M, Rao C, Athanasiou T, Yacoub MH, Terracciano CM. Mechanical unloading and cell therapy have a synergistic role in the recovery and regeneration of the failing heart. Eur J Cardiothorac Surg. 2012 Aug;42(2):312-8. doi: 10.1093/ejcts/ezs067. Epub 2012 Feb 29. Review.</citation>
    <PMID>22378852</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Kyriakos Anastasiadis</investigator_full_name>
    <investigator_title>Associate Professor Kyriakos Anastasiadis</investigator_title>
  </responsible_party>
  <keyword>stem cell implantation</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>left ventricular assist device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

